Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-010-0895-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.
Pediatr Dermatol
September 2024
Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Introduction: At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).
Methods: Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.
Results: 58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.
Aprepitant for severe refractory pruritus in a patient with relapsed Hodgkin lymphoma.
Pediatr Blood Cancer
March 2024
Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan.
Systemic Medication for the Treatment of Prurigo Nodularis-A Systematic Review.
J Cutan Med Surg
November 2023
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Article Synopsis
- - Prurigo nodularis (PN) is a severe skin condition marked by itchy red or purple lesions, and treating it effectively requires a combination of therapies that tackle both immune and nerve-related issues.
- - A comprehensive review of 1,153 articles led to the inclusion of 88 studies focused on various systemic treatments for PN, highlighting the efficacy of drugs like dupilumab, thalidomide, and pregabalin among others.
- - Dupilumab stands out as the most effective treatment with the least side effects, while other medications like thalidomide and pregabalin can cause muscle and nerve pain, and there is a need for more extensive studies on Janus Kinase inhibitors.
Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
Cancer
November 2022
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Background: Pruritus is one of the most common and challenging side effects of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and has impaired patients' quality of life and treatment compliance. Our study evaluated the efficacy and safety of aprepitant in managing EGFR-TKIs-related pruritus.
Methods: This randomized, double-blind, placebo-controlled study was conducted between December 2016 and August 2020 in China.
Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Dermatology
September 2022
Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.
Article Synopsis
- Chronic nodular prurigo (CNPG) is a long-lasting skin condition causing severe itching, and its causes and treatments are not well understood, leading to challenges in management.
- A systematic review found limited literature on therapies for non-atopic CNPG, with too few randomized controlled trials to conduct a meaningful meta-analysis.
- Current treatments explored include nemolizumab and thalidomide, but evidence is inadequate; ongoing RCTs may lead to better-targeted therapies in the future.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!